Trends in diabetic ketoacidosis in Victoria, Australia 2002-2016.
Diabetic ketoacidosis
SGLT2 inhibitors
Type 1 diabetes
Type 2 diabetes
Journal
BMC endocrine disorders
ISSN: 1472-6823
Titre abrégé: BMC Endocr Disord
Pays: England
ID NLM: 101088676
Informations de publication
Date de publication:
29 Jul 2024
29 Jul 2024
Historique:
received:
12
11
2023
accepted:
08
07
2024
medline:
30
7
2024
pubmed:
30
7
2024
entrez:
29
7
2024
Statut:
epublish
Résumé
International longitudinal studies have indicated an increasing incidence of diabetic ketoacidosis (DKA). We aim to examine the incident trends, demographic differences, length of stay and mortality for DKA in adults with type 1 diabetes (T1D) and type 2 diabetes (T2D) in Victoria, Australia from 2002 to 2016. Age and sex adjusted incident trends, length of stay and mortality for DKA was retrospectively obtained using the Victorian Admitted Episode Dataset between 2002 and 2016. Data for adults with T1D and T2D was obtained from the National Diabetes Services Scheme (NDSS). Joinpoint regression analysis was used to identify changes in linear trends that were described as average annual percentage change (AAPC). There were 23,628 DKA presentations in Victoria between 2002 and 2016. For T1D there was an increase in DKA presentations (AAPC + 6.8%) from 2003 to 2016 and for T2D there was a decline from 2003 to 2011 (APC - 3.5%), increase from 2011 to 2014 (APC + 38.5%), and a decrease from 2014 to 2016 (APC - 20.9%). Length of stay was longer for people with T2D than T1D (P < 0.001) and the mortality rate was 0.51% for the study period. DKA rates increased for T2D from 2011 to 2014 which correlates with the introduction of sodium glucose-linked transport protein 2 inhibitors. However, the aetiology for the observed increase in T1D from 2002 to 2016 remains unknown.
Sections du résumé
BACKGROUND
BACKGROUND
International longitudinal studies have indicated an increasing incidence of diabetic ketoacidosis (DKA). We aim to examine the incident trends, demographic differences, length of stay and mortality for DKA in adults with type 1 diabetes (T1D) and type 2 diabetes (T2D) in Victoria, Australia from 2002 to 2016.
METHODS
METHODS
Age and sex adjusted incident trends, length of stay and mortality for DKA was retrospectively obtained using the Victorian Admitted Episode Dataset between 2002 and 2016. Data for adults with T1D and T2D was obtained from the National Diabetes Services Scheme (NDSS). Joinpoint regression analysis was used to identify changes in linear trends that were described as average annual percentage change (AAPC).
RESULTS
RESULTS
There were 23,628 DKA presentations in Victoria between 2002 and 2016. For T1D there was an increase in DKA presentations (AAPC + 6.8%) from 2003 to 2016 and for T2D there was a decline from 2003 to 2011 (APC - 3.5%), increase from 2011 to 2014 (APC + 38.5%), and a decrease from 2014 to 2016 (APC - 20.9%). Length of stay was longer for people with T2D than T1D (P < 0.001) and the mortality rate was 0.51% for the study period.
CONCLUSIONS
CONCLUSIONS
DKA rates increased for T2D from 2011 to 2014 which correlates with the introduction of sodium glucose-linked transport protein 2 inhibitors. However, the aetiology for the observed increase in T1D from 2002 to 2016 remains unknown.
Identifiants
pubmed: 39075462
doi: 10.1186/s12902-024-01650-0
pii: 10.1186/s12902-024-01650-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
128Subventions
Organisme : St Vincent's Hospital Melbourne Research Endowment Fund
ID : 94680
Informations de copyright
© 2024. The Author(s).
Références
Australian Bureau of Statistics. Diabetes [Internet], Canberra. ABS; 2020-21 [cited 2023 January 10]. https://www.abs.gov.au/statistics/health/health-conditions-and-risks/diabetes/latest-release .
Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009;32(7):1335–43.
doi: 10.2337/dc09-9032
pubmed: 19564476
pmcid: 2699725
Zhong VW, Juhaeri J, Mayer-Davis EJ. Trends in Hospital Admission for Diabetic Ketoacidosis in adults with type 1 and type 2 diabetes in England, 1998–2013: a retrospective cohort study. Diabetes Care. 2018;41(9):1870–7.
doi: 10.2337/dc17-1583
pubmed: 29386248
Benoit SR, Hora I, Pasquel FJ, Gregg EW, Albright AL, Imperatore G. Trends in Emergency Department visits and Inpatient admissions for hyperglycemic crises in adults with diabetes in the U.S., 2006–2015. Diabetes Care. 2020;43(5):1057–64.
doi: 10.2337/dc19-2449
pubmed: 32161050
pmcid: 7171947
Morton JI, Lazzarini PA, Shaw JE, Magliano DJ. Trends in the incidence of hospitalization for major diabetes-related complications in people with type 1 and type 2 diabetes in Australia, 2010–2019. Diabetes Care. 2022;45(4):789–97.
doi: 10.2337/dc21-2268
pubmed: 35085387
Hamblin PS, Wong R, Ekinci EI, Fourlanos S, Shah S, Jones AR, et al. SGLT2 inhibitors increase the risk of Diabetic Ketoacidosis developing in the community and during Hospital Admission. J Clin Endocrinol Metab. 2019;104(8):3077–87.
doi: 10.1210/jc.2019-00139
pubmed: 30835263
Riveline JP, Roussel R, Vicaut E, De Pouvourville G, Detournay B, Emery C, et al. Reduced rate of Acute Diabetes events with flash glucose monitoring is sustained for 2 years after initiation: extended outcomes from the RELIEF study. Diabetes Technol Ther. 2022;24(9):611–8.
doi: 10.1089/dia.2022.0085
pubmed: 35604792
Pasquel FJ, Messler J, Booth R, Kubacka B, Mumpower A, Umpierrez G, et al. Characteristics of and Mortality Associated with Diabetic Ketoacidosis among US patients hospitalized with or without COVID-19. JAMA Netw Open. 2021;4(3):e211091–e.
doi: 10.1001/jamanetworkopen.2021.1091
pubmed: 33688962
pmcid: 7948057
The International statistical. classification of diseases and related health problems, tenth revision, Australian modification (ICD-10-AM). In: Health NCfCi, editor. 7th edition ed. Lidcombe, NSW2010.
Kiburg KV, MacIsaac AI, Wilson A, Sundararajan V, MacIsaac RJ. Hospital admissions for cardiovascular complications of people with or without diabetes, Victoria, 2004–2016. Med J Aust. 2021;215(2):85–6.
doi: 10.5694/mja2.51101
pubmed: 34028039
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.
doi: 10.1016/0021-9681(87)90171-8
pubmed: 3558716
Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19(3):335–51.
doi: 10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z
pubmed: 10649300
McCoy RG, Herrin J, Galindo RJ, Swarna KS, Umpierrez GE, Golden SH, et al. Rates of hypoglycemic and hyperglycemic emergencies among U.S. adults with diabetes, 2011–2020. Diabetes Care. 2022;46(2):e69–71.
doi: 10.2337/dc22-1673
pmcid: 9887609
Alshami A, Purewal T, Douedi S, Alazzawi M, Hossain MA, Ong R et al. Effect of insulin pump use on Diabetic Ketoacidosis in Type 1 diabetes Mellitus: a matched cohort study. J Clin Med. 2021;10(5).
Venkatesh N, Astbury N, Thomas MC, Rosado CJ, Pappas E, Krishnamurthy B, et al. Severe acute respiratory syndrome coronavirus 2 as a potential cause of type 1 diabetes facilitated by spike protein receptor binding domain attachment to human islet cells: an illustrative case study and experimental data. Diabet Med. 2021;38(11):e14608.
doi: 10.1111/dme.14608
pubmed: 34043837
pmcid: 8236964
Weber C, Kocher S, Neeser K, Joshi SR. Prevention of diabetic ketoacidosis and self-monitoring of ketone bodies: an overview. Curr Med Res Opin. 2009;25(5):1197–207.
doi: 10.1185/03007990902863105
pubmed: 19327102
Larsson CR, Januszewski AS, McGrath RT, Ludvigsson J, Keech AC, MacIsaac RJ, et al. Suboptimal behaviour and knowledge regarding overnight glycaemia in adults with type 1 diabetes is common. Intern Med J. 2018;48(9):1080–6.
doi: 10.1111/imj.13798
pubmed: 29573166
Johnson SR, Holmes-Walker DJ, Chee M, Earnest A, Jones TW, Group AS, et al. Universal Subsidized continuous glucose Monitoring Funding for Young People with type 1 diabetes: Uptake and Outcomes over 2 years, a Population-based study. Diabetes Care. 2022;45(2):391–7.
doi: 10.2337/dc21-1666
pubmed: 34872983
Chandrashekar M, Philip S, Nesbitt A, Joshi A, Perera M. Sodium glucose-linked transport protein 2 inhibitors: an overview of genitourinary and perioperative implications. Int J Urol. 2021;28(10):984–90.
doi: 10.1111/iju.14624
pubmed: 34155680
Sodium glucose co-transport 2 inhibitors: Australian Government Department of Health and Aged Care. 2018 [ https://www.tga.gov.au/news/safety-alerts/sodium-glucose-co-transporter-2-inhibitors .
Jensen ET, Stafford JM, Saydah S, D’Agostino RB, Dolan LM, Lawrence JM, et al. Increase in Prevalence of Diabetic ketoacidosis at diagnosis among Youth with type 1 diabetes: the SEARCH for diabetes in Youth Study. Diabetes Care. 2021;44(7):1573–8.
doi: 10.2337/dc20-0389
pubmed: 34099516
pmcid: 8323183
Holman N, Woch E, Dayan C, Warner J, Robinson H, Young B, et al. National trends in Hyperglycemia and Diabetic Ketoacidosis in Children, adolescents, and young adults with type 1 diabetes: a challenge due to Age or Stage of Development, or is new thinking about Service Provision needed? Diabetes Care. 2023;46(7):1404–8.
doi: 10.2337/dc23-0180
pubmed: 37216620
pmcid: 10300515
Shou J, Chen PJ, Xiao WH. Mechanism of increased risk of insulin resistance in aging skeletal muscle. Diabetol Metab Syndr. 2020;12:14.
doi: 10.1186/s13098-020-0523-x
pubmed: 32082422
pmcid: 7014712
MacIsaac RJ, Lee LY, McNeil KJ, Tsalamandris C, Jerums G. Influence of age on the presentation and outcome of acidotic and hyperosmolar diabetic emergencies. Intern Med J. 2002;32(8):379–85.
doi: 10.1046/j.1445-5994.2002.00255.x
pubmed: 12162394
Clapin HF, Earnest A, Colman PG, Davis EA, Jefferies C, Anderson K, et al. Diabetic Ketoacidosis at Onset of type 1 diabetes and long-term HbA1c in 7,961 children and young adults in the Australasian Diabetes Data Network. Diabetes Care. 2022;45(12):2918–25.
doi: 10.2337/dc22-0853
pubmed: 36749868